.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Fuji
Express Scripts
US Department of Justice
UBS
Chinese Patent Office
Boehringer Ingelheim
Julphar
Teva
Novartis

Generated: November 17, 2017

DrugPatentWatch Database Preview

Aspirin; dipyridamole - Generic Drug Details

« Back to Dashboard

What are the generic sources for aspirin; dipyridamole and what is the scope of aspirin; dipyridamole patent protection?

Aspirin; dipyridamole
is the generic ingredient in two branded drugs marketed by Barr, Sandoz Inc, Par Pharm Inc, Zydus Pharms Usa Inc, Impax Labs Inc, Boehringer Ingelheim, and Amneal Pharms, and is included in seven NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Aspirin; dipyridamole has thirty-two patent family members in twenty-four countries and three supplementary protection certificates in three countries.

There are twenty-one drug master file entries for aspirin; dipyridamole. Eleven suppliers are listed for this compound.

Summary for aspirin; dipyridamole

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Impax Labs Inc
ASPIRIN AND DIPYRIDAMOLE
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL206964-001Jan 18, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Barr
ASPIRIN AND DIPYRIDAMOLE
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL078804-001Aug 14, 2009ABRXNoNo► Subscribe► Subscribe► Subscribe
Zydus Pharms Usa Inc
ASPIRIN AND DIPYRIDAMOLE
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL206753-001Aug 29, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm Inc
ASPIRIN AND DIPYRIDAMOLE
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL207944-001Jan 18, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
ASPIRIN AND DIPYRIDAMOLE
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL206739-001Jan 18, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Boehringer Ingelheim
AGGRENOX
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL020884-001Nov 22, 1999ABRXYesYes► Subscribe► Subscribe ► Subscribe
Amneal Pharms
ASPIRIN AND DIPYRIDAMOLE
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL206392-001Mar 8, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: aspirin; dipyridamole

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim
AGGRENOX
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL020884-001Nov 22, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: aspirin; dipyridamole

Country Document Number Estimated Expiration
European Patent Office0257344► Subscribe
Norway873370► Subscribe
Australia7679587► Subscribe
South Africa8705947► Subscribe
Israel83510► Subscribe
Philippines27176► Subscribe
Norway175132► Subscribe
HungaryT44937► Subscribe
Ireland872152► Subscribe
Hungary202404► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ASPIRIN; DIPYRIDAMOLE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/043United Kingdom► SubscribePRODUCT NAME: DIPYRIDAMOLE, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT, AND O-ACETYLSALICYLIC ACID, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY SALT, I.E. ASASANTIN RETARD; REGISTERED: FR NL 22160 19970709; UK 00015/0224 19980512
/1999Austria► SubscribePRODUCT NAME: DIPYRIDAMOL IN KOMBINATION MIT ACETYLSALICYLSAEURE; NAT. REGISTRATION NO/DATE: 1-22779 19981112; FIRST REGISTRATION: FR NL 22160 19970709
90001Netherlands► SubscribePRODUCT NAME: DIPYRIDAMOL, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AAN- VAARDBAAR ZOUT, EN ACETYLSALICYLZUUR, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT,IN EEN GEWICHTSVERHOUDING TUSSEN DIPYRIDAMOL-BESTANDDEEL EN ACETYLSALICYLZUUR-BESTANDDE; NAT. REGISTRATION NO/DATE: RVG 21171 19980713; FIRST REGISTRATION: FR 343 234.9, 560 483.7 19970709
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Colorcon
Harvard Business School
McKesson
Chinese Patent Office
Mallinckrodt
Fish and Richardson
Federal Trade Commission
US Army
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot